The efficacy of anti-PD-1 agents in acral and mucosal melanoma.

ABSTRACT:

Background

Therapeutic antibodies against programmed cell death receptor 1 (PD-1) are considered front-line therapy in metastatic melanoma. The efficacy of PD-1 blockade for patients with biologically distinct melanomas arising from acral and mucosal surfaces has not been well described.

Methods

A multi-institutional, retrospective cohort analysis identified adults with advanced acral and mucosal melanoma who received treatment with nivolumab or pembrolizumab as standard clinical practice through expanded access programs or published prospective trials. Objective responses were determined using investigator-assessed Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. Progression-free survival and overall survival were assessed using the Kaplan-Meier method.

SUBMITTER: Shoushtari AN 

PROVIDER: S-EPMC5134420 | biostudies-literature | 2016 Nov

REPOSITORIES: biostudies-literature